Activity

05), nor in the tPSA level or the results of DRE and MRI at 12, 24, 36, 48 and over 48 months (P > 0.05). CONCLUSIONS SABT is safe for PCa patients undergoing radical prostatectomy and does not increase the tumor recurrence rate after surgery.Objective To explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) versus conventional intensity-modulated radiation therapy (IMRT) in the treatment of prostate cancer. METHODS Forty patients with localized prostate adenocarcinoma received SBRT for 5 doses totaling 36.25 Gy (n = 20) or IMRT for 42 doses totaling 75.6 Gy (n = 20). We compared the post-therapeutic PSA levels and related toxic reactions between the two groups of patients and recorded the rates of 5-year overall survival and freedom from biochemical failure (FFBF). RESULTS The minimum level of PSA was 0.41 (0－1.25) μg/L at 2 years and 0.22 (0.1－1.4) μg/L at 3 years after radiotherapy in the SBRT group, significantly lower than 0.62 (0－2.4) μg/L and 0.47 (0－2.5) μg/L in the IMRT group (P less then 0.05), while the time to the minimum PSA level was markedly shorter in the IMRT than in the SBRT group (27.9 ［1.0－40.8］ vs 33.6 ［2.7－41.6］ mo, P less then 0.05). Selleck Poly(vinyl alcohol) The change rate of the PSA level was remarkably higher in the SBRT than in the IMRT group at 2 and 3 years after treatment (－0.06 and －0.05 μg/L/mo vs －0.04 and －0.02 μg/L/mo, P less then 0.05). No statistically significant difference was observed in the 5-year overall survival between the SBRT and IMRT groups (91.1% vs 86.7%, P = 0.158). CONCLUSIONS SBRT and IMRT are comparable in therapeutic effect and toxicity, but the former has the advantages of low cost and convenient application and is therefore more suitable as an alternative treatment of localized prostate cancer.Objective To investigate the necessity of medication for patients with type Ⅲ prostatitis-like symptoms for less than 3 months. METHODS We enrolled in this study 171 outpatients with type Ⅲ prostatitis-like symptoms for less than 3 months in our hospital from November 2016 to October 2017, and randomly divided them into groups A (n = 57), B (n = 57) and C (n = 57). The patients of group A received tamsulosin, levofloxacin and health education, those of group B tamsulosin and health education, and those of group C health education only. Three months later, we evaluated the therapeutic effects according to the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores of the patients, 4-point reduction in the total score indicating effectiveness. RESULTS After 3 months of treatment, the total NIH-CPSI scores of the patients in groups A, B and C were decreased by (9.0 ± 2.9), (8.2 ± 3.4) and (8.6 ± 3.2) points respectively, all indicating effectiveness, the pain scores (4.2 ± 1.8), (4.0 ± 1.9) and (4.2 ± 1.6) points, the urinary symptom scores decreased by decreased by (2.4 ± 1.2), (2.4 ± 1.4) and (2.2 ± 1.2) points, and quality of life scores decreased by (2.4 ± 1.4), (1.9 ± 1.4) and (2.2 ± 1.3) points, none with statistically significant difference among the three groups (P > 0.05). CONCLUSIONS Health education is proved to have a therapeutic effect on type Ⅲ prostatitis-like symptoms similar to that of alpha receptor blockers.Objective To investigate the surgical techniques and clinical effect of Memokath transurethral spiral thermo-expandable prostatic stent (STEPS) implantation in the treatment of BPH. METHODS From January 2017 to January 2018, 26 BPH patients underwent Memokath transurethral STEPS implantation, 9 under the flexible cystoscope and the other 17 under the rigid cystoscope. The patients were aged 62－91 years old, with a prostate volume of 32－78 ml, postvoid residual urine volume (PVR) of (67.3 ± 11.2) ml, maximum urinary flow rate (Qmax) of (6.3 ± 1.8) ml/s, and IPSS score of 26.7 ± 5.7. Eight of the patients had preoperative urinary retention, of whom, 6 received catheterization and 2 had undergone cystostomy for bladder fistula before STEPS implantation. RESULTS The operations lasted 15－30 minutes and were successfully completed in 24 cases while stent-shedding occurred in the other 2. Twenty-two of the patients achieved spontaneous urination immediately after surgery and 2 experienced bladder clot embolism. At 3 month after surgery, 24 of the patients showed significant improvement in PVR (［21.4 ± 7.7］ ml), Qmax (［18.3 ± 4.7］ ml/s) and IPSS (8.3 ± 2.1), and 13 exhibited no statistically significant difference from the baseline in the IIEF-5 score (14.1 ± 1.1 vs 14.3 ± 1.0, P > 0.05). At 12 months, all the patients were found with markedly improved urination but no adverse events except recurrent urinary tract infection in 2 cases. CONCLUSIONS Memokath STEPS implantation, with its advantages of simple operation, high safety, definite effectiveness, non-influence on sexual function, is a new effective surgical option for the treatment of BPH.Objective To assess the clinical value and safety of pelvic MRI combined with transurethral ultrasound (TRUS)-guided transperineal template mapping biopsy (TTMB) in the diagnosis of prostate cancer. METHODS A total of 164 men underwent MRI plus TRUS-guided TTMB for the diagnosis of prostate cancer from December 2015 to May 2018. The patients averaged 71.2 years of age and, based on the PSA level, were divided into four groups PSA 100 μg/L groups (P less then 0.01), but not between the PSA less then 10 μg/L and PSA 10－20 μg/L groups (P = 0.086). CONCLUSIONS Pelvic MRI combined with TRUS-guided X+12-core TTMB, with the advantages of high accuracy and low rate of complications, is an ideal approach to the diagnosis of prostate cancer.Objective To evaluate the efficiency and safety of transurethral holmium laser enucleation of the prostate (HoLEP) in the treatment of BPH in patients with a history of transrectal prostate biopsy (TRPB). METHODS We retrospectively analyzed the clinical data on 102 cases of BPH treated by HoLEP in our hospital between November 2015 and May 2017, of which 42 had received TRPB prior to HoLEP (the PB group) but not the other 60 (the non-TRPB ［NPB］ group). We compared the preoperative, perioperative and postoperative follow-up data between the two groups of patients. RESULTS There were no statistically significant differences in the mean age, prostate volume, and preoperative post-void residual urine volume (PVR), IPSS, quality of life (QOL) score and maximum urinary flow rate (Qmax) between the two groups of patients. The preoperative PSA level was significantly higher in the PB than in the NPB group (［10.30 ± 3.62］ vs ［2.62 ± 1.75］ μg/L, P less then 0.01), and the operation time markedly longer in the former than in the latter (［78.